This notion is supported by a study in which overexpression of programmed cell death protein-1 (PD-1) and BCL2 and increased activity of the AKT/mTOR pathway were observed in CLL patients who developed progressive disease or Richter’s transformation following treatment with ibrutinib[50]. Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.